1	Masseter Muscle Volume and Its Association with Sarcopenia and Muscle
2	Determinants with Insights from ACTN3 Polymorphism in Older Japanese Adults:
3	the Bunkyo Health Study
4	

Abulaiti Abudurezake <sup>1</sup>, Saori Kakehi <sup>1,2</sup>, Futaba Umemura <sup>2</sup>, Hideyoshi Kaga <sup>3</sup>, Yuki
Someya <sup>4</sup>, Hiroki Tabata <sup>1</sup>, Yasuyo Yoshizawa <sup>5</sup>, Hitoshi Naito <sup>3</sup>, Tsubasa Tajima <sup>3</sup>, Naoaki
Ito <sup>3</sup>, Hikaru Otsuka <sup>2</sup>, Huicong Shi <sup>2</sup>, Mari Sugimoto <sup>2</sup>, Shota Sakamoto <sup>2</sup>, Yukiko Muroga
<sup>2</sup>, Hidetaka Wakabayashi <sup>6</sup>, Ryuzo Kawamori <sup>123</sup>, Hirotaka Watada <sup>1,3</sup>, Yoshifumi Tamura
<sup>1,2,3,5,7</sup>

1	Λ
T	υ

<sup>11</sup> <sup>1</sup>Sportology Center, Graduate School of Medicine, Juntendo University.

<sup>12</sup> <sup>2</sup>Department of Sports Medicine and Sportology, Graduate School of Medicine, Juntendo

13 University.

<sup>14</sup> <sup>3</sup>Metabolism and Endocrinology, Graduate School of Medicine, Juntendo University.

<sup>4</sup>Graduate School of Health and Sports Science, Juntendo University.

<sup>16</sup> <sup>5</sup>Center for Healthy Life Expectancy, Graduate School of Medicine, Juntendo University.

<sup>6</sup>Department of Rehabilitation Medicine, Tokyo Women's Medical University.

<sup>7</sup>Faculty of International Liberal Arts, Juntendo University.

19

20 Short title: Masseter Muscle Volume in Older Japanese Adults

21

- 22 Word count:
- 23 Abstract: 247 words

24 Text: 3074 words

- 25 Number of figures and tables: 5
- 26

# 27 Corresponding author:

- 28 Saori Kakehi, PhD
- 29 Sportology Center, Graduate School of Medicine, Juntendo University
- 30 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
- 31 Tel: +81-3-3813-3111
- 32 Fax: +81-3-3813-5996
- 33 E-mail: <u>skakei@juntendo.ac.jp</u>
- 34

35 Abstract

36

37 Aim

Sarcopenia has been associated with a decrease in masseter muscle (MM) thickness in
high-risk older populations. However, the relationship to sarcopenia and determinants of
MM volume (MMV) in the general older population remain unclear.

41

#### 42 Method

In a cross-sectional study of 1484 older adults of Tokyo, we evaluated MMV using 3D
MRI scanning, appendicular skeletal muscle mass (ASMM), handgrip strength, dietary
intake, smoking, insulin-like growth factor 1 (IGF-1) levels, and the ACTN3 R577X
polymorphism. Participants were divided into quintiles based on MMV (Q1-5).

47

#### 48 **Results**

49 Our study of participants with a mean age of  $73.0 \pm 5.3$  years, MMV (Men:  $35.3 \pm 7.8$  ml, 50 Women:  $25.0 \pm 5.1$  ml) was significantly larger in men than in women. A significant 51 association between MMV and sarcopenia was observed, with the lowest quintile (Q1) 52 showing a higher risk compared to the highest quintile (Q5) in both sexes. Body mass 53 index (BMI) and age were independent determinants of ASMM in both sexes, while BMI, 54 but interestingly not age, was a determinant of MMV. Moreover, IGF-1 was positively 55 correlated with MMV in both sexes; smoking negatively correlated with MMV in women. The ACTN3 577X polymorphism was associated with only smaller MMV in men. 56

57

# 58 **Conclusion**

- 59 Low MMV increased the risk of sarcopenia, particularly in men. BMI and age strongly
- 60 influenced ASMM, while MMV was only weakly associated with BMI and not with age.
- 61 Notably, the IGF-1 level was positively correlated to only MMV, and the ACTN3
- 62 genotype was linked to reduced only MMV in men.
- 63
- 64

65	Key	words
----	-----	-------

- 66 Sarcopenia, masseter muscle volume, general older population, ACTN3 577XX genotype,
- 67 insulin-like growth factor 1

#### 68 Introduction

69

The rise in the number of older individuals requiring care is a grave issue in aging societies(1). One potential solution to this problem lies in preventative measures that reduce the risk of needing care. Sarcopenia, a condition characterized by diminished muscle mass, reduced muscle strength, and compromised physical function(2, 3), contributes significantly to the increased risk of mortality and the need for care(4, 5). Thus, it is presumed that the prevention of sarcopenia plays a pivotal role in mitigating care requirements.

77 Several risk factors have been associated with an increased risk of sarcopenia, 78 including aging(6), reduced BMI(7), decreased physical activity(8), and cerebrovascular 79 disorders(9). Two previous studies highlighted the relationship between masseter muscle 80 (MM) thickness and sarcopenia (10, 11). In these studies, a mere 1-mm increase in MM 81 thickness, as measured by ultrasound, significantly decreased the risk of sarcopenia by 82 ~45% and ~57% in older patients hospitalized for hip fractures and those in nursing homes, respectively. In addition, MM thickness was significantly associated with skeletal 83 84 mass index (SMI) in community-dwelling older people(12). Given these findings, it is 85 reasonable to expect that decreased MM volume (MMV) may also be associated with 86 sarcopenia in the general older population. However, the potential association between 87 MMV and formally diagnosed sarcopenia, as defined by the Asian Working Group for Sarcopenia (AWGS) 2019 (3), in this population remains unexplored. Another issue is 88 89 that the aforementioned studies measured muscle size using ultrasound, which is not the 90 most accurate method(13). CT or MRI scans are superior because they provide detailed three-dimensional images that enable more precise measurement of muscle volume. In
particular, although CT and MRI scans of the head have been performed in older people,
MM has not been analyzed at all, and it would be clinically useful to identify standard
MMV values and risk prediction thresholds.

Even if an association is observed between MMV and sarcopenia, the determinants of each may be different. It is rare for MM to contract in relation to physical activity or to exert maximal muscle force(14, 15), and therefore it differs from skeletal muscles of the extremities, which are active during physical activity. Therefore, comparing the determinants of appendicular skeletal muscle mass (ASMM) and MMV may provide important insights into why MMV is associated with sarcopenia, and may yield a deeper understanding of the mechanisms of muscle mass regulation.

102 Genetic factors are determinants of skeletal muscle mass and function(16-19), 103 and one of the most extensively studied genes in this context is the  $\alpha$ -actinin-3 gene. The 104 protein  $\alpha$ -actinin-3, coded by ACTN3, forms part of the Z-line of muscle fibers(20) and is 105 specifically expressed only in fast-twitch skeletal muscle fibers(14). Notably, 106 homozygosity for a common nonsense polymorphism (R577X) in the ACTN3 gene results 107 in a complete deficiency of  $\alpha$ -actinin-3, and in animal models, the lack of actn3 leads to 108 a reduction in both muscle mass, mainly type II fibers, and muscle strength(21). Indeed, 109 the ACTN3 577XX  $\alpha$ -actinin-3 null genotype is significantly underrepresented in elite 110 sprint athletes(22), and it increases the risk of sarcopenia in older people (19, 23). 111 However, it remains unclear whether the ACTN3 577XX null genotype is associated with 112 reduced MMV.

113

Against this background, our study aimed to clarify the relationship between

- 114 MMV (determined through 3D reconstruction of MRI images) and sarcopenia in older
- 115 Japanese people. Furthermore, we compared the determinants of MMV and ASMM,
- 116 including genetic polymorphisms of *ACTN3*.

- 117 Research Design and Methods
- 118

## 119 Study Design and Participants

120 This cross-sectional study used baseline data from the Bunkyo Health Study(1). Briefly, 121 in this study, we recruited individuals aged between 65-84 years living in Bunkyo-ku, an 122 urban area in Tokyo, Japan. The Bunkyo Health Study registry initially enrolled 1629 123 individuals. From this cohort, we excluded 64 participants who either lacked head MRI 124 data or image slices that included the masticatory muscles. Additionally, among the 125 remaining 1565 participants, 66 diagnosed with cerebrovascular disorders and 15 with 126 unavailable data (body composition [n = 2], physical function [n = 3], genetic type [n =127 7]) were also excluded from the study. Consequently, the final sample for this analysis 128 comprised 1484 participants (603 men, 881 women) (Figure S1). All participants 129 completed the examinations at the Sportology Center from October 15, 2015, to October 130 1, 2018. The study protocol was approved by the ethics committee of Juntendo University 131 in November 2015 (Nos. 2015078, 2016138, 2016131, 2017121, and 2019085). This 132 study was carried out in accordance with the principles outlined in the Declaration of 133 Helsinki. All participants gave written informed consent and were informed that they had 134 the right to withdraw from the trial at any time.

135

#### 136 **3D Assessment of MMV**

Total MMV was measured by selecting and extracting the data captured by MRI with a 3D medical image analysis system, and reconstructing these data in 3D (24). MRI was performed in the supine position with the occlusion relaxed. All head MRI data (2-mm-

140	wide T2-weighted images taken with a 0.3 T MRI, Hitachi, Ltd.) were imported into the
141	workstation software application, AZE Medical Image Processor (AZE Virtual Place,
142	Canon Medical Co., Ltd.). For each slice, the masticatory muscles were selected and
143	extracted using a semi-automatic function (Figure S2). The MM was then reconstructed
144	using the contour trace function. We performed color mapping to ensure that the entire
145	MM was visible, and the volume was measured using the 3D volumetry function (Figure
146	S2, 3). We used the mean value of the left and right MMVs. A.A. measured all MMVs,
147	and the intraclass correlation coefficient and its 95% confidence interval (CI) were 0.944
148	and 0.989–0.997, respectively.
149	
150	Body composition measurements
151	ASMM was evaluated with bioelectrical impedance analysis (InBody770, InBody Japan
152	Inc., Tokyo, Japan), and the SMI was calculated (ASMM/height <sup>2</sup> ).
153	
154	Genotyping
155	Genomic DNA was isolated from whole blood using the standard method (RNeasy Blood
156	and Tissue DNA Extraction Kit, QIAGEN, Minneapolis, MN, USA). All participants
157	were genotyped for the ACTN3 R577X (rs1815739) polymorphism using the Infinium
158	Asian Screening Array-24 v1.0 BeadChip (Illumina, San Diego, CA, USA).
159	
160	Other measurements
161	Handgrip strength (HGS) was measured using a handgrip dynamometer (T.K.K. 5401,

162 Takei Scientific Instruments, Niigata, Japan) with the arm held to the side of the body.

Physical activity level was evaluated using the International Physical Activity 163 164 Questionnaire, which assesses different types of physical activity, such as walking and 165 both moderate- and high-intensity activities(25). As part of the survey on dietary history, 166 participants completed the brief diet history questionnaire (BDHQ)(26). Based on responses to the question about smoking, cumulative cigarette consumption was 167 168 expressed as the Brinkman index (cigarette consumption per day multiplied by the number of years smoking)(27). Insulin-like growth factor 1 (IGF-1) levels were measured 169 170 in blood samples collected from participants after an overnight fast.

171

#### 172 **Definition of sarcopenia**

Sarcopenia was defined as weak HGS (<28 kg for men and <18 kg for women) and low</li>
ASMM (<7.0 kg/m<sup>2</sup> for men and <5.7 kg/m<sup>2</sup> for women) based on the definition of the
AWGS 2019 (3).

176

#### 177 Statistical analyses

All statistical calculations were performed using IBM SPSS Statistics for Windows 178 179 version 25 (IBM, Armonk, NY). Data are presented as means  $\pm$  SD or number (%). 180 Differences between sexes were determined using Student's t-test for continuous variables and the  $\chi^2$  test for non-continuous variables (Table 1). Participants were divided into 181 182 quintiles based on the MMV for each sex (quintiles 1-5: Q1-5). Differences in means and proportions were evaluated using ANOVA and the  $\chi^2$  test (Table 2). Differences in 183 characteristics between genotypes (Table 4) were compared using ANOVA and the  $\chi^2$  test. 184 Adjustments for multiple comparisons were performed using post hoc Bonferroni 185

186	correction. Logistic regression was used to estimate odds ratios (ORs) and 95%
187	confidence intervals (CIs) for the prevalence of each outcome in each group, compared
188	with the reference group. Multiple linear regression was used to examine factors affecting
189	MMV or ASMM in each group. Potential confounders were based on previous reports
190	that have identified factors such as BMI, physical activity level, protein intake, diabetes,
191	smoking, and IGF-1 as being associated with muscle mass or muscle strength(7, 8, 28),
192	these factors were included as confounders in our analysis. All statistical tests were two-
193	sided with a 5% significant level.

- 194 **Results**
- 195

## 196 Characteristics of study participants

197 Characteristics of the study participants are shown in Table 1. Of 1,484 participants 198 (average age  $73.0 \pm 5.3$  years), 603 were men (average age  $72.9 \pm 5.3$  years) and 881 were 199 women (average age  $73.0 \pm 5.4$  years). The MMV and SMI were about 1.4 and 1.3 times 200 greater in men than in women, respectively, indicating a significant difference in both 201 cases. HGS was 1.5 times greater in men than in women, also a significant difference. 202 The prevalence of diabetes was significantly higher in men at 16.5% compared to women 203 at 7.8%. The prevalence of sarcopenia was comparable between men and women, at 204 12.4% in men and 11.7% in women.

205

#### 206 Association between MMV and various body composition indices

207 MMV was divided into quintiles and clinical features were compared (Table 2). In men, 208 Q1, representing the lowest MMV, was associated with the lowest values among the 209 groups for all clinical features other than age and physical activity, and was associated 210 with the highest proportions of participants with low SMI, low HGS, and sarcopenia. 211 Compared to Q1, there were significant differences between groups in terms of height 212 (against Q3, 4, 5), weight (against Q4, 5), BMI (against Q5), ASMM (against Q3, 4, 5), 213 SMI (against Q3, 4, 5), HGS (against Q2, 3, 4, 5), and IGF-1 (for Q3, 4, 5). Similar trends 214 were observed in women. Compared to Q1, there were significant differences between 215 groups in weight (against Q2, 3, 5), BMI (against Q5), ASMM (against Q2, 3, 4, 5), SMI 216 (against Q2, 3, 4, 5), HGS (against Q3, 4, 5), and IGF-1 (for Q3, 5).

217

#### 218 Relationship between MMV and sarcopenia

219 To clarify whether decreased MMV was independently associated with the prevalence of 220 sarcopenia, we conducted a logistic regression analysis (Table 3). After adjusting for age 221 and BMI in Model 1, Q1 was associated with a significantly higher OR for the prevalence 222 of sarcopenia compared to Q5 in both men and women (men, OR: 6.624, 95% CI: 2.175-223 20.178, p < 0.001; women, OR: 2.178, 95% CI: 1.044–4.546, p = 0.038), and the OR for 224 Q2 in men was also significantly different relative to Q5 (OR: 3.440, 95% CI: 1.078-225 10.976, p = 0.037). In model 2, which adjusted for physical activity, protein intake, 226 Brinkman index, and IGF-1, the ORs of Q1 in men (OR: 6.573, 95% CI: 2.101-20.559, p = 0.001) and in women (OR: 2.192, 95% CI: 1.033-4.652, p = 0.041) were still 227 228 significant compared to Q5.

229

### 230 Relationship between ACTN3 R577X polymorphism and MMV

Next, we examined the association between MMV or ASMM and ACTN3 577XX genotypes. The samples exhibited no deviation from the Hardy-Weinberg equilibrium. As shown in Table 4, in men with the ACTN3 577XX genotype, MMV was significantly lower compared to other genotypes, but ASMM was similar across genotypes. In contrast, no association was found between genotype and either MMV or ASMM in women.

236

#### 237 Multiple regression model of factors predicting MMV or ASMM

We next performed a multiple regression analysis to identify the independent determinants of MMV and ASMM (Table 5). In the total variance explained by the model,

 $R^2$  was much lower in MMV than in ASMM in both sexes. This difference was mainly 240 241 due to the much more significant standardized  $\beta$  values of BMI and age for ASMM than 242 for MMV in both sexes. BMI was positively correlated (men,  $\beta = 0.618$ ; women,  $\beta =$ 0.600) and age was negatively correlated (men,  $\beta = -0.296$ ; women,  $\beta = 0.246$ ) with 243 ASMM in both sexes, while BMI (men,  $\beta = -0.168$ ; women,  $\beta = -0.110$ ), but interestingly 244 245 not age, was positively correlated with MMV. In addition, IGF-1 was positively correlated 246 with MMV in both sexes, while smoking was negatively correlated with MMV in women. 247The ACTN3 577X polymorphism in men, but not in women, was associated with smaller 248 MMV, which was consistent with the analysis in Table 4.

#### 249 **Discussion**

250

251 In the present study, we measured MMV in community-dwelling older people in Japan 252 and investigated its relationship with sarcopenia. Furthermore, we compared 253 determinants of MMV and ASMM, including genetic polymorphisms of ACTN3. Our 254 findings indicated that men in the group with the lowest MMV had a 6.9-fold increased 255 risk of sarcopenia, while women had a 2.1-fold increased risk, compared to those in the 256group with the highest MMV. Multiple regression analysis revealed that both BMI and 257 age were independent determinants of ASMM in both sexes. However, for MMV, the 258 ACTN3 genotype and IGF-1 were independent determinants in men, whereas smoking 259 and IGF-1 emerged as significant factors in women.

260 The present study revealed an association between MMV and sarcopenia, which 261 is consistent with the findings of prior cohort studies (10, 11) that utilized ultrasound to 262 measure MMT. Importantly, our participants were community-dwelling individuals who 263 were over a decade younger (73 years old) compared to those in previous studies (86 or 264 84.7 years old), and were either hospitalized for hip fractures or who resided in nursing 265 homes(10, 11). In this large-scale study, we found a substantial rise in the OR of 266 sarcopenia in men within the two lowest quintiles of MMV (Q1 and Q2) when compared 267 to the group with the largest MMV (Q5). Conversely, in women, a significant increase in 268 OR was only observed in Q1, although it was not as pronounced as in men. Moreover, 269 the OR gradually increased as MMV decreased in women, while in men, a mild although 270 not significant rise was detected in Q3 and Q4. Thus, despite gender differences, a trend 271 toward an increased risk of sarcopenia with decreasing MMV was observed in both men and women.

273 This study revealed specific differences were observed between men and women 274 regarding the relationship between MMV and sarcopenia. In fact, after full adjustment, 275 the OR for the lowest quintile (Q1) in men (OR: 6.573) was 3 times higher than that in 276 women (OR: 2.192). This might be because men and women have different types of 277 muscle fibers in their MMs. Age-related muscle atrophy occurs preferentially in type II 278 muscle fibers(29), and it is known that the proportion of type II muscle fibers in the MM 279 is higher in men than in women(30). Additionally, age-related loss of muscle mass is also 280 more likely to occur in men(31). Given these factors, it is plausible that MMV serves as 281 a more sensitive indicator of age-related muscle atrophy in men compared to women.

282 Previous studies have investigated the link between ACTN3 R577X and muscle 283 mass in older people, but the results have been inconsistent. These discrepancies might 284 arise from variations in sample sizes or the diverse ages and backgrounds of the 285 participants. While some studies(19, 32, 33) found that people with the ACTN3 577XX 286 null genotype were more likely to lose muscle mass, others did not observe this link(34-36). The present study did not find that ACTN3 R577X was related to ASMM, but it was 287 288 notably associated with MMV, particularly in men. The  $\alpha$ -actinin-3 protein, encoded by 289 ACTN3, is specifically expressed in fast-twitch skeletal muscle fibers(14), and the 290 proportion of type II muscle fibers in MM is higher in men than in women(30). In addition, 291 the lack of Actn3 leads to a reduction in muscle mass in mice, predominantly in type II 292 fibers(21), and the muscle mass reduction with age was also enhanced in Actn3-deficient mice, especially males(37). These findings may explain why there was an association 293 294 between MMV and ACTN3R577X in men but not women. The lack of a clear association

between ACTN3 R577X and ASMM, in contrast to MMV, may arise because factors such
as BMI strongly influence ASMM, masking potential genetic differences. Similarly, even
though IGF-1 is known to induce skeletal muscle hypertrophy(38), in our study it was
associated with MMV, not ASMM, possibly due to the overriding effect of BMI on
ASMM.

300 This study identified BMI and age as major determinants of ASMM. 301 Interestingly, however, while the association between BMI and MMV was moderate, that 302 between age and MMV was not significant. This discrepancy can be attributed to the 303 functional differences between the two muscle types. ASM contains a higher proportion 304 of antigravity muscles and is influenced by weight-bearing, whereas MM is primarily 305 active during mastication. The increased weight-bearing due to a higher BMI can lead to 306 an increase in ASMM. It is known that high weight-bearing loads predominantly result in 307 hypertrophy of type II muscle fibers, which are more susceptible to age-related 308 atrophy(29). In contrast, studies have shown that MM contains a higher percentage of 309 type I fibers compared to ASM(39). We hypothesize that these differences in fiber type 310 composition and function might explain why age affects ASM, but not MMV.

This study highlights the importance of MMV as a key marker for sarcopenia risk, particularly among older Japanese men. Since CT and MRI scans of the head are occasionally performed in the older people, it would be clinically useful to identify sarcopenia risk by performing an additional MMV analysis. In addition, clinicians should note the differential impact of BMI and age on ASMM compared to MMV, with the latter showing no association with age. Additionally, the ACTN3 577X genotype presents a unique genetic dimension, influencing MMV predominantly in men. Understanding these facts can facilitate more precise early detection of sarcopenia, as well as interventionstailored to specific gender and genetic profiles.

320 This study has several limitations. Because this cohort included only people 321 living in urban areas of Japan, our results may not be applicable to people living in other 322 parts of Japan or in other countries. In addition, since this was a cross-sectional study, we 323 could not establish any causal relationships. Therefore, further prospective longitudinal 324 studies are needed to clarify the association between MMV and the development of 325 sarcopenia. In addition, since we were unable to obtain information on the remaining teeth, 326 denture status, existence of temporomandibular joint disorder, and bruxism existence of 327 the participants in this study. Accordingly, recent data suggested that the ACTN3 R557X 328 polymorphism may influence bruxism in patients with dentofacial deformity(40). 329 Therefore, further studies addressing these factors are needed.

In conclusion, low MMV was a risk factor for sarcopenia, with the effect being more pronounced in men than in women. While BMI and age were strong determinants of ASMM, only a weak association was observed between BMI and MMV, with no correlation between age and MMV. Notably, the IGF-1 level was positively correlated to MMV, but not ASMM, and the ACTN3 577X genotype linked to reduced MMV in men but showed no association with ASMM in either sex.

18

## 336 Funding

337 This study was supported by Strategic Research Foundation at Private Universities

338 (S1411006) and KAKENHI (18H03184) grants from the Ministry of Education, Culture,

339 Sports, Science, and Technology of Japan, the Mizuno Sports Promotion Foundation, and

- 340 the Mitsui Life Social Welfare Foundation.
- 341

## 342 Acknowledgments

343 The authors would like to thank all staff for their contributions to data collection at the

- 344 Sportology Center.
- 345

## 346 **Duality of Interest**

347 The authors have nothing to disclose.

348

# 349 Supplemental Figure legends

n	ΓΛ	
3	<b>5</b> 0	

## 351 Figure S1 Flow chart of subject inclusion and exclusion criteria.

352

353 Figure S2 Steps for the assessment of MMV. All head MRI data are imported into the

354 workstation software. The masseter muscle is selected and extracted. (a) The color 355 mapping operation screen is shown. (b) The diaphragm is reconstructed. (c) The volume

- is measured.
- 357
- 358 Figure S3 Masseter muscle reconstructed after selective extraction.

#### 359 (References)

360

Someya Y, Tamura Y, Kaga H, Nojiri S, Shimada K, Daida H, et al. Skeletal muscle
 function and need for long-term care of urban elderly people in Japan (the Bunkyo Health Study):
 a prospective cohort study. BMJ Open. 2019;9(9):e031584.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al.
 Sarcopenia: European consensus on definition and diagnosis: Report of the European Working
 Group on Sarcopenia in Older People. Age and Ageing. 2010;39(4):412-23.

Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working
 Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am
 Med Dir Assoc. 2020;21(3):300-7.e2.

Sawaya Y, Ishizaka M, Kubo A, Shiba T, Hirose T, Onoda K, et al. The Asian working
 group for sarcopenia's new criteria updated in 2019 causing a change in sarcopenia prevalence in
 Japanese older adults requiring long-term care/support. Journal of Physical Therapy Science.
 2020;32(11):742-7.

5. Ping Liu QH, Shan Hai, Hui Wang, Li Cao and B Dong. Sarcopenia as a predictor of allcause mortality among community-dwelling older people: A systematic review and meta-analysis
- ClinicalKey. Maturitas. 2017;103:16-22.

Wu LC, Kao HH, Chen HJ, Huang PF. Preliminary screening for sarcopenia and related
risk factors among the elderly. Medicine (Baltimore). 2021;100(19):e25946.

379 7. Nakanishi S, Iwamoto M, Shinohara H, Iwamoto H, Kaneto H. Significance of body mass
380 index for diagnosing sarcopenia is equivalent to slow gait speed in Japanese individuals with type
381 2 diabetes: Cross-sectional study using outpatient clinical data. J Diabetes Investig.
382 2021;12(3):417-24.

Kitamura M, Izawa KP, Ishihara K, Matsuda H, Okamura S, Fujioka K. Physical Activity
 and Sarcopenia in Community-Dwelling Older Adults with Long-Term Care Insurance. European
 Journal of Investigation in Health, Psychology and Education. 2021;11(4):1610-8.

386 9. Li W, Yue T, Liu Y. New understanding of the pathogenesis and treatment of stroke387 related sarcopenia. Biomed Pharmacother. 2020;131:110721.

388 10. González-Fernández M, Perez-Nogueras J, Serrano-Oliver A, Torres-Anoro E, Sanz389 Arque A, Arbones-Mainar JM, et al. Masseter Muscle Thickness Measured by Ultrasound as a
390 Possible Link with Sarcopenia, Malnutrition and Dependence in Nursing Homes. Diagnostics.
391 2021;11(9):1587.

392 11. Sanz-Paris A, González-Fernandez M, Hueso-Del Río LE, Ferrer-Lahuerta E, Monge393 Vazquez A, Losfablos-Callau F, et al. Muscle Thickness and Echogenicity Measured by Ultrasound
394 Could Detect Local Sarcopenia and Malnutrition in Older Patients Hospitalized for Hip Fracture.
395 Nutrients. 2021;13(7):2401.

12. Umeki K, Watanabe Y, Hirano H, Edahiro A, Ohara Y, Yoshida H, et al. The relationship

- between masseter muscle thickness and appendicular skeletal muscle mass in Japanese
   community-dwelling elders: A cross-sectional study. Arch Gerontol Geriatr. 2018;78:18-22.
- 399 13. Reis Durão AP, Morosolli A, Brown J, Jacobs R. Masseter muscle measurement
  400 performed by ultrasound: a systematic review. Dentomaxillofacial Radiology.
  401 2017;46(6):20170052.
- 402 14. Miyamoto K, Ishizuka Y, Tanne K. Changes in masseter muscle activity during
  403 orthodontic treatment evaluated by a 24-hour EMG system. Angle Orthod. 1996;66(3):223-8.
- 404 15. Mew JR. The postural basis of malocclusion: a philosophical overview. Am J Orthod
  405 Dentofacial Orthop. 2004;126(6):729-38.
- 406 16. Huang Y, Bodnar D, Chen CY, Sanchez-Andrade G, Sanderson M, Biogen Biobank T,
  407 et al. Rare genetic variants impact muscle strength. Nat Commun. 2023;14(1):3449.
- 408 17. Roth SM. Genetic aspects of skeletal muscle strength and mass with relevance to409 sarcopenia. Bonekey Rep. 2012;1:58.
- 410 18. Charlier R, Caspers M, Knaeps S, Mertens E, Lambrechts D, Lefevre J, et al. Limited
  411 potential of genetic predisposition scores to predict muscle mass and strength performance in
  412 Flemish Caucasians between 19 and 73 years of age. Physiol Genomics. 2017;49(3):160-6.
- 413 19. Cho J, Lee I, Kang H. ACTN3 Gene and Susceptibility to Sarcopenia and Osteoporotic
  414 Status in Older Korean Adults. Biomed Res Int. 2017;2017:4239648.
- 20. Beggs AH, Byers TJ, Knoll JH, Boyce FM, Bruns GA, Kunkel LM. Cloning and
  characterization of two human skeletal muscle alpha-actinin genes located on chromosomes 1 and
  11. J Biol Chem. 1992;267(13):9281-8.
- 418 21. MacArthur DG, Seto JT, Chan S, Quinlan KG, Raftery JM, Turner N, et al. An Actn3
  419 knockout mouse provides mechanistic insights into the association between alpha-actinin-3
  420 deficiency and human athletic performance. Hum Mol Genet. 2008;17(8):1076-86.
- 421 22. North KN, Yang N, Wattanasirichaigoon D, Mills M, Easteal S, Beggs AH. A common
  422 nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat Genet.
  423 1999;21(4):353-4.
- 424 23. Kiuchi Y, Makizako H, Nakai Y, Taniguchi Y, Tomioka K, Sato N, et al. Associations of
  425 alpha-actinin-3 genotype with thigh muscle volume and physical performance in older adults with
  426 sarcopenia or pre-sarcopenia. Exp Gerontol. 2021;154:111525.
- 427 24. Abudurezake A, Morita T, Mori T, Amano A. Validity of Diaphragm Volume
  428 Measurements Using Three-Dimensional Computed Tomography. Juntendo Medical Journal.
  429 2022;68(5):481-90.
- Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al.
  International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports
  Exerc. 2003;35(8):1381-95.
- 433 26. Kobayashi S, Murakami K, Sasaki S, Okubo H, Hirota N, Notsu A, et al. Comparison of
  434 relative validity of food group intakes estimated by comprehensive and brief-type self-

435 administered diet history questionnaires against 16 d dietary records in Japanese adults. Public
436 Health Nutr. 2011;14(7):1200-11.

437 27. Brinkman GL, Coates EO, Jr. The effect of bronchitis, smoking, and occupation on
438 ventilation. Am Rev Respir Dis. 1963;87:684-93.

439 28. Roh E, Choi KM. Health Consequences of Sarcopenic Obesity: A Narrative Review.
440 Front Endocrinol (Lausanne). 2020;11:332.

29. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type
specificity in muscle wasting. Int J Biochem Cell Biol. 2013;45(10):2191-9.

30. Tuxen A, Bakke M, Pinholt EM. Comparative data from young men and women on
masseter muscle fibres, function and facial morphology. Archives of Oral Biology. 1999;44(6):50917.

Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al. The
loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body
composition study. J Gerontol A Biol Sci Med Sci. 2006;61(10):1059-64.

32. Zempo H, Tanabe K, Murakami H, Iemitsu M, Maeda S, Kuno S. ACTN3 polymorphism
affects thigh muscle area. Int J Sports Med. 2010;31(2):138-42.

33. Kahraman M, Ozulu Turkmen B, Bahat-Ozturk G, Catikkas NM, Oren MM, Sahin A, et
al. Is there a relationship between ACTN3 R577X gene polymorphism and sarcopenia? Aging Clin
Exp Res. 2022;34(4):757-65.

454 34. Bustamante-Ara N, Santiago C, Verde Z, Yvert T, Gomez-Gallego F, Rodriguez-Romo
455 G, et al. ACE and ACTN3 genes and muscle phenotypes in nonagenarians. Int J Sports Med.
456 2010;31(4):221-4.

35. San Juan AF, Gomez-Gallego F, Canete S, Santiago C, Perez M, Lucia A. Does complete
deficiency of muscle alpha actinin 3 alter functional capacity in elderly women? A preliminary
report. Br J Sports Med. 2006;40(1):e1.

460 36. MacArthur DG, North KN. ACTN3: A genetic influence on muscle function and athletic
461 performance. Exerc Sport Sci Rev. 2007;35(1):30-4.

37. Seto JT, Chan S, Turner N, MacArthur DG, Raftery JM, Berman YD, et al. The effect of
alpha-actinin-3 deficiency on muscle aging. Exp Gerontol. 2011;46(4):292-302.

38. Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy:
implications in health and disease. Nat Commun. 2021;12(1):330.

39. Sciote JJ, Rowlerson AM, Hopper C, Hunt NP. Fibre type classification and myosin
isoforms in the human masseter muscle. J Neurol Sci. 1994;126(1):15-24.

468 40. Nicot R, Raoul G, Vieira AR, Ferri J, Sciote JJ. ACTN3 genotype influences masseter
469 muscle characteristics and self-reported bruxism. Oral Dis. 2023;29(1):232-44.

470

	All	Men	Women	p value
N	1,484	603	881	
Age (years)	$73.0\pm5.3$	$72.9\pm5.3$	$73.0\pm5.4$	0.716
Masseter muscle volume (ml)	$29.2\pm8.1$	$35.3\pm7.8$	$25.0\pm5.1$	< 0.001
Height (cm)	$157.9\pm8.7$	$165.8\pm5.9$	$152.4\pm5.5$	< 0.001
Weight (kg)	$56.9 \pm 10.2$	$64.6\pm8.6$	$51.7\pm7.6$	< 0.001
Body mass index (kg/m <sup>2</sup> )	$22.7\pm3.1$	$23.5\pm2.8$	$22.2\pm3.2$	< 0.001
Appendicular skeletal muscle mass (kg)	$16.2\pm3.9$	$20.2\pm2.6$	$13.5\pm1.8$	< 0.001
Skeletal muscle index (kg/m <sup>2</sup> )	$6.4\pm1.0$	$7.3\pm0.6$	$5.8\pm0.6$	< 0.001
Hand grip strength (kg)	$25.7\pm7.0$	$32.4\pm5.4$	$21.2\pm3.5$	< 0.001
Total physical activity (Mets*hour/week)	$44.2\pm48.7$	$48.3\pm56.8$	$41.4\pm42.0$	0.007
Low SMI (%)	38.2	30.8	43.2	< 0.001
Low hand grip strength (%)	18.7	21.6	16.7	0.018
Sarcopenia (%)	12.0	12.4	11.7	0.664
Energy intake (kcal/day)	$1959.6\pm597.7$	$2139.7\pm629.3$	$1836.3\pm541.9$	< 0.001
Protein intake (g/day)	$83.0\pm30.7$	$83.9\pm30.4$	$82.3\pm30.8$	0.325
Brinkman index	$246.8\pm471.9$	$512.3\pm594.0$	$65.1\pm229.2$	< 0.001
IGF-1 (ng/mL)	$93.4\pm29.4$	$98.0\pm28.8$	$90.3\pm29.4$	< 0.001
Diabetes (%)	11.4	16.6	7.8	< 0.001

Table 1 Characteristics of the study participants.

Data are expressed as mean  $\pm$  SD. p values are derived from the Student's t-test for continuous variables and the  $\chi^2$  test for non-continuous variables.

Table 2 Characteristics of study participants by MMV quintiles in men (a) and women (b)

	``
	<u> </u>
	aı
•	,

MMV quintile in men ( <i>n</i> )	Q1 (120)	Q2 (120)	Q3 (121)	Q4 (121)	Q5 (121)	p value
Mean MMV	$25.3\pm2.8$	$30.6\pm1.1$	$34.5\pm1.2$	$39.2\pm1.4$	$47.0\pm4.2$	
(Min~Max) (ml)	(16.2~28.5)	(28.6~32.4)	(32.5~36.7)	(36.8~41.8)	(41.8~59.5)	-
Age (years)	$73.8\pm5.8$	$73.4\pm5.6$	$72.3\pm5.0$	$72.5\pm5.0$	$72.6\pm4.9$	0.128
Height (cm)	$163.8\pm5.5~^{\text{b,c,d}}$	$165.0\pm5.7^{\rm \ d}$	$166.1\pm5.6$	$166.4\pm5.7$	$167.9\pm6.5$	< 0.001
Weight (kg)	$61.8\pm8.2^{\text{ c,d}}$	$63.8\pm8.2^{\text{ d}}$	$63.6\pm7.8^{\ d}$	$65.3\pm8.5^{\text{ d}}$	$68.5\pm8.9$	< 0.001
Body mass index (kg/m <sup>2</sup> )	$23.0\pm2.7^{\text{ d}}$	$23.4\pm2.7$	$23.1\pm2.6^{\rm \ d}$	$23.6\pm2.8$	$24.3\pm2.9$	< 0.001
ASMM (kg)	$18.9\pm2.4^{\text{ b,c,d}}$	$19.7\pm2.4^{\text{ d}}$	$20.1\pm2.2^{\text{ d}}$	$20.5\pm2.6^{\text{ d}}$	$21.7\pm2.6$	< 0.001
SMI (kg/m <sup>2</sup> )	$7.0\pm0.6^{\text{ b,c,d}}$	$7.2\pm0.6^{\text{ d}}$	$7.3\pm0.5^{\rm \ d}$	$7.4\pm0.6^{\rm \ d}$	$7.7\pm0.6$	< 0.001
Hand grip strength (kg)	$29.7\pm4.8^{\rm \ a,d,c,d}$	$32.0\pm4.9^{\text{ d}}$	$32.2\pm4.6^{d}$	$33.5\pm5.7$	$34.4\pm5.7$	< 0.001
Total PA (Mets*hour/week)	$52.8\pm 64.8$	$41.6\pm48.6$	$50.0\pm50.4$	$52.4\pm73.3$	$44.6\pm40.5$	0.453
Low SMI (%)	48.3	36.7	28.9	27.30	13.20	< 0.001
Low hand grip strength (%)	35.0	24.20	19.0	16.5	13.2	< 0.001
Sarcopenia (%)	25.0	13.3	9.9	10.7	3.3	< 0.001
Energy intake (kcal/day)	$2132.9\pm563.1$	$2065.1\pm570.7$	$2136.1\pm673.3$	$2167.8\pm650.5$	$2196.0\pm 680.8$	0.574
Protein intake (g/day)	$86.3\pm29.5$	$77.9\pm25.8$	$82.0\pm30.0$	$85.9\pm30.9$	$87.6\pm34.6$	0.086
Brinkman index	$544.9\pm612.5$	$495.2\pm596.9$	$535.8\pm 622.0$	$484.7\pm511.1$	$501.0\pm 627.3$	0.917
IGF-1 (ng/mL)	$88.5 \pm 22.2^{d,c,d}$	$94.1\pm29.7^{\rm \ d}$	$100.8\pm27.8$	$100.4\pm28.4$	$105.6\pm32.2$	< 0.001
Diabetes (%)	15.8	13.3	16.5	19.0	18.2	0.790

MMV quintile in women ( <i>n</i> )	Q1 (177)	Q2 (176)	Q3 (176)	Q4 (176)	Q5 (176)	p value
Mean MMV	$18.5 \pm 1.8$	$22.1 \pm 0.8$	$24.5 \pm 0.7$	$27.4 \pm 1.0$	32.6 ± 3.2	
(Min~Max) (ml)	(13.2~20.8)	(20.8~23.4)	(23.4~25.8)	(25.8~29.1)	(29.2~46.3)	-
Age (years)	$73.5\pm5.9$	$72.9\pm5.6$	$73.4\pm5.6$	$72.8\pm5.0$	$72.6\pm4.8$	0.466
Height (cm)	$151.7\pm5.4$	$152.5\pm5.6$	$152.9\pm6.0$	$152.3\pm5.2$	$152.8\pm5.5$	0.244
Weight (kg)	$49.5\pm7.4^{\rm \ a,b,d}$	$52.3\pm8.5$	$52.2\pm7.6$	$51.2\pm6.6$	$53.0\pm7.3$	< 0.001
Body mass index (kg/m <sup>2</sup> )	$21.6\pm3.3^{\ d}$	$22.5\pm3.3$	$22.3\pm2.9$	$22.1\pm2.9$	$22.8\pm3.2$	0.006
ASMM (kg)	$12.9\pm1.8^{\rm \ a,b,c,d}$	$13.5\pm1.9$	$13.6\pm1.9$	$13.6\pm1.7$	$13.9\pm1.7$	< 0.001
SMI (kg/m <sup>2</sup> )	$5.6\pm0.6^{\rm \ a,b,c,d}$	$5.8\pm0.6$	$5.8\pm0.5$	$5.8\pm0.5$	$6.0\pm0.5$	< 0.001
Hand grip strength (kg)	$20.2\pm3.7^{\text{ b,c,d}}$	$20.9\pm3.5^{\ d}$	$21.3\pm3.5$	$21.8\pm3.4$	$22.0\pm3.2$	< 0.001
Total PA (Mets*hour/week)	$47.2\pm54.4$	$37.4\pm39.6$	$41.9\pm42.5$	$41.1\pm37.3$	$39.4 \pm 32.8$	0.255
Low SMI (%)	58.2	46.0	42.6	39.8	29.5	< 0.001
Low hand grip strength (%)	23.7	18.8	17.6	14.2	9.1	0.005
Sarcopenia (%)	18.6	13.1	11.9	8.0	6.8	0.005
Energy intake (kcal/day)	$1862.8\pm588.3$	$1780.1\pm545.9$	$1855.5\pm506.2$	$1847.5\pm518.9$	$1835.6\pm548.4$	0.625
Protein intake (g/day)	$82.1\pm32.8$	$79.4\pm29.0$	$84.3\pm29.6$	$84.5\pm32.5$	$81.5\pm30.3$	0.509
Brinkman index	$68.8\pm241.3$	$100.7\pm321.5$	$72.6\pm230.4$	$51.3 \pm 169.9$	$32.3\pm132.8$	0.068
IGF-1 (ng/mL)	$82.5\pm22.7^{\text{ b,d}}$	$90.4\pm27.1$	$94.2\pm25.2$	$89.1\pm23.3$	$95.2\pm42.4$	< 0.001
Diabetes (%)	7.3	9.7	8.0	7.4	6.8	0.882

Abbreviations: MMV, masseter muscle volume; PA, physical activity; ASMM, appendicular skeletal muscle mass; SMI, skeletal muscle index. p value: one-way ANOVA for continuous variables and  $\chi^2$  test for non-continuous variables p < 0.05: a vs Q2; b vs Q3; c vs Q4; d vs Q5 for Bonferroni post hoc test.

			Mei	n		
		Model 1			Model 2	
	OR	95% CI	p value	OR	95% CI	p value
Q5		Reference			Reference	
Q4	3.147	0.967-10.242	0.057	2.985	0.901-9.891	0.074
Q3	2.468	0.747-8.154	0.138	2.395	0.715-8.018	0.157
Q2	3.440	1.078-10.976	0.037	3.007	0.916-9.869	0.069
Q1	6.624	2.175-20.178	< 0.001	6.573	2.101-20.559	0.001
Age	1.122	1.066-1.181	< 0.001	1.109	1.052-1.170	< 0.001
Body mass index	0.708	0.629-0.796	< 0.001	0.702	0.622-0.793	< 0.001
Total physical activity				0.991	0.983-0.999	0.036
Protein intake				0.993	0.982-1.003	0.188
Brinkman index			1.000	0.999-1.000	0.124	
Diabetes			2.272	1.152-4.480	0.018	
IGF-1				0.993	0.982-1.004	0.187

Table 3 Odds ratios for sarcopenia by MMV quintiles in men (a) and women (b): results of a binomial logistic regression analysis.

# (a)

Women						
		Model 1			Model 2	
	OR	95% CI	p value	OR	95% CI	p value
Q5		Reference			Reference	
Q4	0.913	0.396-2.106	0.831	0.910	0.390-2.128	0.829
Q3	1.387	0.635-3.033	0.412	1.381	0.627-3.041	0.424
Q2	1.723	0.797-3.721	0.166	1.621	0.741-3.546	0.227
Q1	2.178	1.044-4.546	0.038	2.192	1.033-4.652	0.041
Age	1.192	1.140-1.247	< 0.001	1.195	1.141-1.252	< 0.001
Body mass index	0.785	0.723-0.854	< 0.001	0.776	0.712-0.845	< 0.001
Total physical activity				0.997	0.991 - 1.002	0.242
Protein intake				0.995	0.988-1.003	0.203
Brinkman index				1.000	0.999-1.001	0.447
Diabetes				2.309	1.164-4.580	0.017
IGF-1				1.001	0.994-1.008	0.812

Data are expressed as odds ratios (OR, 95% CIs). Binomial logistic analysis was performed with age and BMI as covariates for Model 1, and Model 2 added total activity, protein intake, Brinkman index, diabetes, and IGF-1 to Model 1.

	Men				Women			
	RR	RX	XX	p value	RR	RX	XX	p value
N	131	298	174		186	461	234	
Age (years)	$72.7\pm5.6$	$72.8\pm5.1$	$73.3\pm5.3$	0.490	$73.1\pm5.6$	$72.7\pm5.3$	$73.6\pm5.5$	0.130
Height (cm)	$166.1\pm5.6$	$165.8\pm6.0$	$165.6\pm6.1$	0.840	$152.6\pm5.8$	$152.3\pm5.6$	$152.6\pm5.2$	0.688
Weight (kg)	$65.2\pm9.4$	$64.8\pm8.5$	$63.8 \pm 8.2$	0.350	$51.3\pm8.1$	$51.5\pm7.3$	$52.2\pm7.6$	0.399
BMI $(kg/m^2)$	$24.0\pm2.8$	$23.9\pm2.7$	$23.6\pm2.8$	0.499	$22.4\pm3.2$	$22.7\pm3.2$	$22.8\pm3.1$	0.415
MMV (ml)	$36.4\pm7.8$	$35.8\pm8.0$	$33.0\pm7.5~^{\rm a}$	0.009	$25.0\pm5.1$	$25.0\pm5.3$	$24.9\pm4.8$	0.980
SMI (kg/m <sup>2</sup> )	$7.3\pm0.7$	$7.4\pm0.7$	$7.2\pm0.6$	0.108	$5.8\pm0.6$	$5.8\pm0.6$	$5.8\pm0.5$	0.303
ASMM (kg)	$22.0\pm3.1$	$22.0\pm3.0$	$21.4\pm2.7$	0.097	$15.0\pm2.2$	$15.1\pm1.9$	$15.4\pm2.1$	0.082
Hand grip strength (kg)	$32.5\pm3.3$	$32.7\pm5.6$	$31.7\pm5.1$	0.167	$21.4\pm3.4$	$21.1\pm3.7$	$21.3\pm3.3$	0.562
Total PA (Mets*hour/week)	$48.11\pm74.00$	$48.81\pm50.33$	$47.54\pm52.33$	0.972	$39.12\pm38.04$	$41.84\pm42.20$	$42.29 \pm 44.69$	0.703
Low SMI (%)	32.6	28.5	33.5	0.467	47.3	43.2	40.2	0.340
Low hand grip strength (%)	9.8	9.1	15.6	0.080	12.9	18.9	15.4	0.151
Sarcopenia (%)	12.9	10.7	15.0	0.391	10.8	11.5	12.0	0.927
Protein intake (g/day)	$84.7\pm28.5$	$83.7\pm31.3$	$83.7\pm30.4$	0.947	$81.4\pm30.6$	$82.3\pm30.3$	$83.2\pm32.3$	0.838
Brinkman index	$573.8\pm598.7$	$490.3\pm602.1$	$503.2\pm576.2$	0.395	$84.0\pm286.5$	$57.4\pm202.6$	$65.4\pm227.5$	0.409
IGF-1 (ng/mL)	$96.7\pm24.7$	$99.8\pm30.7$	$95.8\pm28.5$	0.285	$93.4\pm43.4$	$91.0\pm24.0$	$86.6\pm24.5$	0.052
Diabetes (%)	17.4	18.1	13.3	0.381	5.4	6.9	11.5 ª	0.039

Table 4 Characteristics of older participants by ACTN3 R577X genotype.

Data are expressed as mean  $\pm$  SD.

Abbreviations: MMV, masseter muscle volume; ASMM, appendicular skeletal muscle mass; SMI, skeletal mass index; BMI, body mass index p value:  $\chi^2$  test for non-continuous variables. Continuous variables were analyzed by one way ANOVA. p < 0.05: a vs RR and RX for Bonferroni post hoc test.

	Men				Women				
	MMV		ASMM		MMV		ASMM		
	β	p value							
actn3	-0.100	0.011	-0.032	0.280	0.003	0.940	0.058	0.058	
Age	-0.047	0.250	-0.296	< 0.001	-0.048	0.173	-0.246	< 0.001	
Body mass index	0.168	< 0.001	0.618	< 0.001	0.110	0.001	0.600	< 0.001	
Total physical activity	-0.016	0.685	0.017	0.578	-0.020	0.549	-0.004	0.870	
Protein intake	0.044	0.272	0.017	0.581	0.042	0.217	0.048	0.076	
Brinkman index	-0.023	0.573	0.002	0.949	-0.072	0.032	-0.019	0.488	
Diabetes	0.060	0.134	0.011	0.721	-0.011	0.745	-0.031	0.250	
IGF-1	0.173	< 0.001	0.028	0.366	0.129	< 0.001	0.042	0.128	
$R^2$	0.086*		0.474*		0.042*		0.391*		

Table 5 Association of each factor with MMV or ASMM in a multiple regression model

\*p < 0.001 for analysis of variance